BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease

Brain

Volumn 139, Issue 10, 2016, Pages 2766-2777

  Lim, Yen Ying ^a   Hassenstab, Jason ^b   Cruchaga, Carlos ^b   Goate, Alison ^c   Fagan, Anne M ^b   Benzinger, Tammie L S ^d   Maruff, Paul ^a,e   Snyder, Peter J ^f   Masters, Colin L ^a   Allegri, Ricardo ^g   Chhatwal, Jasmeer ^h   Farlow, Martin R ⁱ   Graff Radford, Neill R ^j   Laske, Christoph ^k,l   Levin, Johannes ^m   McDade, Eric ^b   Ringman, John M ⁿ   Rossor, Martin ^o   Salloway, Stephen ^f   Schofield, Peter R ^p,q   Holtzman, David M ^b   Morris, John C ^b   Bateman, Randall J ^b   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Warren Alpert Medical School of Brown University ^*  (Australia)

^f BROWN UNIVERSITY   (United States)

^g Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^l UNIVERSITY OF TÜBINGEN   (Germany)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^q UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

Alzheimer's disease; amyloid ; dementia; genetics; tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; TAU PROTEIN; UNCLASSIFIED DRUG; VALINE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BRAIN FUNCTION; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; GENE MUTATION; GLUCOSE METABOLISM; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUROIMAGING; PRECUNEUS; PRIORITY JOURNAL; DIAGNOSTIC IMAGING; GENETICS; HETEROZYGOTE; MIDDLE AGED; PHYSIOLOGY;

ADULT; ALZHEIMER DISEASE; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; HETEROZYGOTE; HIPPOCAMPUS; HUMANS; MALE; MEMORY DISORDERS; METHIONINE; MIDDLE AGED; TAU PROTEINS; VALINE;

EID: 84991038728     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww200     Document Type: Article

References (48)

1. Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegenera-tion in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-72.
2. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
3. Belrose JC, Masoudi R, Michalski B, Fahnestock M. Increased pro- nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiol Aging 2013; 35: 926-33.
4. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004; 61: 378-84.
5. Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 2013; 110: E4502-9.
6. Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 2016; 86: 735-41.
7. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107: 22687-92.
8. Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-3.
9. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
10. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 2014; 71: 961-70.
11. Dore V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetelat G, et al. Cross-sectional and longitudinal analysis of the relationship between Ab deposition, cortical thickness, and memory in cogni-tively unimpaired individuals and in Alzheimer's disease. JAMA Neurol 2013; 70: 903-11.
12. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippo-campal function. Cell 2003; 112: 257-69.
13. Elliott E, Atlas R, Lange A, Ginzburg I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of tau protein through a PI-3 kinase signalling mechanism. Eur J Neurosci 2005; 22: 1081-9.
14. Fahnestock M. Brain-derived neurotrophic factor: the link between amyloid-b and memory loss. Future Neurol 2011; 6: 627-39.
15. Feng S, Sevigny J, Verma A, Bennett D, Lim YY, Maruff P. Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations of early Alzheimer's disease. Alzheimers Dement 2013; 9: 178.
16. Ferrer I, Marín C, Rey MJ, Ribalta T, Goutan E, Blanco RT, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease: implications in therapeutic strategies. J Neuropathol Exp Neurol 1999; 58: 729-39.
17. Forlenza OV, Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonça VA, et al. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry 2010; 11: 774-80.
18. Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J Neurosci 2007; 27: 2628-35.
19. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kö vari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60: 1495-500.
20. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184-5.
21. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, Egan MF, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003; 23: 6690-4.
22. Harris SE, Deary IJ. The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn Sci 2011; 15: 388-94.
23. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, et al. Early abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004; 62: 925-31.
24. Ittner LM, Götz J. Amyloid-b and tau - a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12: 65-72.
25. Jack CR, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron 2013; 80: 1347-58.
26. Keaney JFJ, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham study. Arterioscler Thromb Vasc Biol 2003; 23: 434-9.
27. Kim A, Fagan AM, Goate AM, Benzinger TL, Morris JC, Head D, et al. Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. Cogn Affect Behav Neurosci 2015; 15: 625-43.
28. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-8.
29. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, Yoon H, et al. miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Ann Neurol 2012; 72: 269-77.
30. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014a; 137: 221-31.
31. Lim YY, Pietrzak RH, Bourgeat P, Ames D, Ellis KA, Rembach A, et al. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Ab accumulation in cognitively normal older adults and adults with MCI. Arch Clin Neuropsychol 2015a; 30: 49-58.
32. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. BDNF Val66Met moderates Ab-related memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study. PLoS One 2014b; 9: e86498.
33. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, Ellis KA, et al. BDNF Val66Met, Ab amyloid and cognitive decline in pre-clinical Alzheimer's disease. Neurobiol Aging 2013; 34: 2457-64.
34. Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, et al. APOE and BDNF polymorphisms moderate amyloid b-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry 2015b; 20: 1322-8.
35. Lim YY, Villemagne VL, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. APOE "4 moderates amyloid-related memory decline in pre-clinical Alzheimer's disease. Neurobiol Aging 2015c; 36: 1239-44.
36. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P. BDNF-based syn-aptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews, Neuroscience 2013; 14: 401-16.
37. Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol 2013; 169: 737-43.
38. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1983; 43: 2412-14.
39. Morris JC, Aisen PS, Bateman RJ, Benzinger T, Cairns NJ, Fagan AM, et al. Developing an international network for Alzheimer's research: the dominantly inherited Alzheimer etwork. Clin Invest 2012; 2: 975-84.
40. Papenberg G, Salami A, Persson J, Lindenberger U, Bäckman L. Genetics and functional imaging: effects of APOE, BDNF, COMT, and KIBRA in aging. Neuropsychol Rev 2015; 25: 47-62.
41. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. J Neurochem 2005; 93: 1412-21.
42. Rosa E, Fahnestock M. CREB expression mediates amyloid b-induced basal BDNF downregulation. Neurobiol Aging 2015; 36: 2406-13.
43. Rowe CC, Bourgeat P, Ellis KA, Brown B, Lim YY, Mulligan R, et al. Predicting Alzheimer disease with b-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013; 74: 905-13.
44. Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014; 85: 253-60.
45. Spires-Jones T, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014; 82: 756-71.
46. Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014; 28: 19-29.
47. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. NeuroImage 2015; 107: 55-64.
48. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994; 343: 1432-3.